Palvella Therapeutics (Nasdaq: PVLA) announced that CEO and Founder Wes Kaupinen will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9, 2026, at 8:40 a.m. ET.
A live and archived webcast will be available on Palvella's website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – PVLA
-7.03%2.5x vol
35 alerts
-7.03%Session close to close
+5.9%Peak in 6 hr 25 min
$1.66BMarket Cap
2.5xRel. Volume
In the Jun 2 session, PVLA declined 7.03%, reflecting a notable negative market reaction.
Argus tracked a peak move of +5.9% during that session.
Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.
Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
The stock moved -7.0% in the session following this news. A negative reaction despite a routine conf...
Analysis
The stock moved -7.0% in the session following this news. A negative reaction despite a routine conference-participation update fits a recent pattern where PVLA has sometimes traded lower on otherwise constructive news, including uplisting and favorable clinical data. The move could reflect profit-taking after a strong run from the 52-week low of 20.2 to above 112. Investors may watch for how management messaging at the conference reinforces the NDA timeline, commercialization plans, and progress in rare dermatology indications.
Key Figures
Conference edition:47thConference date:June 9, 2026Start time:8:40 a.m. ET+1 more
4 metrics
Conference edition47thGoldman Sachs Annual Global Healthcare Conference 2026
Conference dateJune 9, 2026Scheduled fireside chat date
Start time8:40 a.m. ETFireside chat time at conference
Webcast replay window90 daysArchived replay availability after fireside chat
Transfer of listing from Nasdaq Capital Market to Nasdaq Global Market.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Shares have often traded lower on otherwise positive or neutral news in recent months.
Recent Company History
Over the last few weeks, PVLA has reported several constructive developments. On May 13, it uplisted to the Nasdaq Global Market, yet shares fell -4.15%. New Phase 2 TOIVA data on May 15 and broader SELVA/TOIVA results on May 20 highlighted strong efficacy for QTORIN rapamycin, but one day saw a -3.98% move. A patent-strengthening update on May 27 also coincided with a -1.13% drop. Today’s conference-participation news fits a pattern where favorable or neutral headlines have not consistently driven upside.
Key Terms
clinical-stage, biopharmaceutical, Food and Drug Administration (FDA), webcast
4 terms
clinical-stagemedical
"a clinical-stage biopharmaceutical company focused on developing and commercializing"
Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.
biopharmaceuticalmedical
"a clinical-stage biopharmaceutical company focused on developing and"
A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.
Food and Drug Administration (FDA)regulatory
"for which there are no U.S. Food and Drug Administration (FDA)-approved therapies"
A U.S. government agency that reviews and approves drugs, medical devices, vaccines, food safety measures and related products before they reach the market. Think of it as a gatekeeper whose decisions, inspections and safety warnings can make or break a product’s ability to sell; investors watch FDA actions closely because approvals speed revenue and failed reviews, delays or recalls can sharply change a company’s value.
webcasttechnical
"A live webcast of the fireside chat will be available on the Events"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026 at 8:40 a.m. ET.
A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the fireside chat.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
When will Palvella Therapeutics (PVLA) present at the Goldman Sachs Global Healthcare Conference 2026?
Palvella Therapeutics will present on June 9, 2026, at 8:40 a.m. ET. According to Palvella, CEO Wes Kaupinen will join a fireside chat during the Goldman Sachs 47th Annual Global Healthcare Conference 2026.
How can investors watch Palvella Therapeutics' (PVLA) fireside chat at the Goldman Sachs 2026 healthcare conference?
Investors can watch the fireside chat via a live webcast on Palvella's website. According to Palvella, access will be provided in the Events and Presentations section at www.palvellatx.com.
Will a replay of Palvella Therapeutics' (PVLA) Goldman Sachs 2026 conference webcast be available?
Yes, a replay will be available for approximately 90 days after the event. According to Palvella, the archived webcast can be accessed on the Events and Presentations section of the company’s website.
What type of company is Palvella Therapeutics (PVLA) presenting at the Goldman Sachs 2026 healthcare conference?
Palvella Therapeutics is a clinical-stage biopharmaceutical company. According to Palvella, it focuses on developing novel therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatment options in the United States.
